Exploring novel MYH7 gene variants using in silico analyses in Korean patients with cardiomyopathy

Oc-Hee Kim1, Jihyun Kim1, Youngjun Kim1

  • 1Division of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju, 28159, Republic of Korea.

BMC Medical Genomics
|September 5, 2024
PubMed

Insights

This study identified MYH7 gene variants in Korean cardiomyopathy patients, including novel pathogenic variants. In silico analyses confirmed their potential to cause disease, aiding in improved diagnosis.

Area of Science:

  • Genetics
  • Cardiology
  • Bioinformatics

Background:

  • Pathogenic variants in the MYH7 gene are a significant cause of dilated and hypertrophic cardiomyopathy.
  • MYH7 encodes the beta-myosin heavy chain protein, crucial for cardiac muscle function.

Purpose of the Study:

  • To identify MYH7 gene variants in Korean patients with various cardiomyopathy subtypes.
  • To predict the pathogenicity of novel MYH7 variants using in silico methods.
  • To evaluate the functional and structural impact of identified MYH7 variants.

Main Methods:

  • Whole-genome sequencing was performed on 397 patients.
  • In silico analyses (SIFT, Mutation Assessor, etc.) were used to predict variant pathogenicity.
  • Protein dynamics and stability were assessed using DynaMut2 and Missense3D tools.

Main Results:

  • Twenty-seven MYH7 variants were identified in 41 patients, including 5 novel variants.
  • Pathogenic variants were predominantly located in the myosin motor domain.
  • In silico predictions and functional assessments indicated the novel variants are likely pathogenic.

Conclusions:

  • This study characterizes MYH7 variant distribution in Korean cardiomyopathy patients.
  • In silico tools and functional assessments enhance the understanding of novel variant pathogenicity.
  • Findings offer insights for improved diagnostic strategies for cardiomyopathy.
Abstract

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
828
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
957